Role for CROs as study deems cancer trials biggest risk for Pharmas

By Gareth Macdonald

- Last updated on GMT

Role for CROs as study deems cancer trials biggest risk for Pharmas
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.

The data, from a BIO and BioMedTracker study​, showed that cancer trials have only an 11 per cent chance of success, which is the lowest rate for any of the indications examined.

It also showed that such trials have the second lowest success rate at Phase II and the lowest chance at Phase III, which makes them a considerable investment risk for pharmaceutical firms.

Michael Hay, senior biotechnology analyst at Sagient Research Systems.said that: “Oncology drugs have the toughest time making their way through the clinic, despite cancer being the most closely studied area in drug development.

Having an up-to-date and detailed picture of clinical success rates, and ultimately how likely a drug is to be approved, is vital to our clients when making investment and business decisions.​ “

The report does not discuss the role contract research in making cancer trials more successful but given the increasing practice of trial research outsourcing this is clearly something to be considered.

Further support for this idea comes from data from the Association of Clinical Research Organisations (ACRO) which shows that, in 2008, 18 per cent of its members were involved in cancer trials.

Within this the most the most common areas of research were: Non-small cell lung cancer, breast cancer, lung cancer, prostate cancer, and leukemia.

Oncology Trials Outsourcing

Clearly then, the challenge of conducting a cancer trial is as important an issue to a CRO as it is to a pharmaceutical firm, requiring close collaboration and an effective working relations ship will be holding a virtual event “Oncology Trials Outsourcing,” to provide a forum for pharma firms and research providers to meet, learn and discuss all the issues.

“Oncology Trials Outsourcing,” will feature presentations covering all the latest trends and success strategies in cancer trial outsourcing with topics like strategic partnering to patient recruitment being accompanied by case studies Q&A sessions.

Find out how to register, attend and even take part in this free virtual event from the comfort of your office at the following address.

See you at the conference, virtually.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers